Sign In
Buy BEAM
$29.55
+0.590 (+2.04%)
At Close: Jun 03, 2026
Beam Therapeutics (BEAM) Stock Drops 4% on Clinical Hold News
10:36am, Monday, 01'st Aug 2022
Source: Natali_ Mis/ShutterStock.com Beam Therapeutics (NASDAQ: BEAM ) stock is slipping on Monday after the U.S. Food and Drug Administration (FDA) placed a clinical hold on one of its drugs. Accordi
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
09:31am, Monday, 01'st Aug 2022
The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple. The post FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collap
Beam In On The ARKK Buffet
10:44pm, Sunday, 17'th Jul 2022
Cathie Wood's ARK Innovation ETF is one of the most controversial and followed ETFs. What if you cherry-picked her best ideas.
Revisiting Beam Therapeutics Among Collaborative Catalysts
10:06am, Sunday, 10'th Jul 2022
The recent 4-year partnership between Pfizer and Beam Therapeutics involves $300 million upfront to speed validation of the technology and an additional $1.05 billion in milestone payments. A recent a
Top Health Care Stocks To Buy Right Now? 4 To Watch
02:23pm, Saturday, 09'th Jul 2022
Check these health care stocks out for your watchlist right now
The 3 Leaders of the Gene Editing Revolution
04:12pm, Friday, 08'th Jul 2022
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. The post The 3 Leaders of the Gene Editing Revolution appeared f
7 Moonshot Investments Upending a $10 Trillion Industry
03:53pm, Friday, 08'th Jul 2022
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. The post 7 Moonshot Investments Upending a $10 Trillion Industry appeared first on
Have $1,000 to Invest? 2 Stocks to Buy Right Now That Could Help Make You a Fortune
10:20am, Tuesday, 05'th Jul 2022
These two stocks could generate life-changing gains for patient shareholders.
A Comprehensive Guide to Genomic ETFs
05:43pm, Tuesday, 28'th Jun 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?
10:06am, Monday, 20'th Jun 2022
Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success
02:37pm, Friday, 17'th Jun 2022
BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ: BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-gener
EV Industry Reward-Risk Map
04:55pm, Thursday, 09'th Jun 2022
Stocks tied broadly to the electric vehicle charging industry, as listed today by Seeking Alpha, are shown by their Market-Maker-valued price range limits on 6/8/22 close prices. No comment necessary.
5 Health Care Stocks Cathie Wood Favors
04:07pm, Thursday, 09'th Jun 2022
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
3 Cathie Wood Stocks That Could Deliver Monster Returns
09:00am, Saturday, 04'th Jun 2022
Here's why our roundtable likes 10x Genomics, Beam Therapeutics, and Recursion Pharmaceuticals.
